Phase II study of alternating doses of vinorelbine in combination with cisplatin for non-small cell lung cancer (NSCLC): A disappointing experience

Lung Cancer

Volumn 16, Issue 1, 1996, Pages 61-73

  Westeel, Virginie ^a   Jacoulet, Pascale ^a   Breton, Jean Luc ^b   Garnier, Gaston ^b   Mercier, Mariette ^c   Depierre, Alain ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b CHG   (France)

^c UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

alternating doses; dose intensity; non small cell lung cancer; phase II study; vinorelbine cisplatin

Indexed keywords

CISPLATIN; NAVELBINE;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEATH; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OTOTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0031040329     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(96)00612-5     Document Type: Article

References (36)

1. [1] Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Survival determinants in extensive stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618-1626.
2. [2] Ashizawa T, Asada M, Kobayashi E, Okabe M, Gomi K, Hirata T. Combination effect of navelbine (vinorelbine ditartrate) with cisplatin against murine p388 leukemia and human lung carcinoma xenografts in mice. Anti-Cancer Drugs 1993; 4: 577-583.
3. [3] Baldini E, Tibaldi C, Chella A, Angeletti CA, Romanini A, Andrei A, Algeri R, Silvano G, Conte PF. Combination chemotherapy with vinorelbine, ifosfamide and cisplatin: a Phase II study in Stage IIIB-IV non-small cell lung cancer. Semin Oncol 1994; 21 (suppl 4): 12-15.
4. [4] Berthaud P, Le Chevalier T, Ruffie P, Baldeyrou P, Arriagada R, Besson F, Tursz T. Phase I-II study of vinorelbine (navelbine) plus cisplatin in advanced non-small cell lung cancer. Eur J Cancer 1992; 11: 1863-865.
5. [5] Brooks BJ, Gralla RJ, McGaw HJ, Otten MC, Lang AC, Rittenberg CN. Cisplatin + vinorelbine (navelbine) combination chemotherapy for advanced non-small cell lung cancer: testing the efficacy of a regimen designed to reduce toxicity and increase dose-intensity. Proc Am Soc Clin Oncol 1994; 13: A348.
6. [6] Crawford J, O'Rourke MA. Vinorelbine (navelbine)/ carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor. Semin Oncol 1994 (suppl 10); 21: 73-78.
7. [7] Depierre A, Chastang C, Quoix E, Lebeau B, Blanchon F, Paillot N, Lemarie E, Milleron B, Moro B, Clavier J, Herman D, Tuchais E, Jacoulet P, Brechot JM, Cordier JF, Solal-Celigny P, Badri N, Besenval M. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 1994; 5: 37-42.
8. [8] Depierre A, Lemarie E, Dabouis G, Gamier G, Jacoulet P, Dalphin JC. A Phase II study of navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol 1991; 14: 115-119.
9. [9] Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei EF, Green MR. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in Stage III non-small cell lung cancer. N Engl J Med 1990; 323: 940-945.
10. [10] Drinkard L, Samuels B, Hoffman P, Golomb H, Bitran J, Ferguson Watson S, Haraf D, Vokes E. A Phase I-II trial of cisplatin (CDDP), 5-fluorouracil (5FU), leucovorin (PFL) and navelbine (NVB) in advanced non-small cell lung cancer (NSCLC). Lung Cancer 1994; 11 (suppl 1): A466.
11. [11] Furuse K, Kubota K, Kawahara M, Ogawara M, Kinuwaki E, Motomiya M, Nishiwaki Y, Niitani H, Sakuma A, the Japan Vinorelbine Lung Cancer Study Group. A Phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Lung Cancer 1994; 11: 385 391.
12. [12] Gralla RJ, Kardinal CG, Otten MC, Brooks BJ, Rittenberg CN. Vinorelbine (navelbine) in combination with cisplatin or mitomycin: enhancing safety, efficacy and dose-intensity. Lung Cancer 1994; 11 (suppl 1): A456.
13. [13] Gralla RJ, Kardinal CG, Clark RA, Otten MC, Hanson DS. Enhancing the safety, efficacy and dose-intensity of vinorelbine (navelbine) in combination chemotherapy regimens. Proc Am Soc Clin Oncol 1993; 12: A1122.
14. [14] Gralla RJ, Hesketh PJ, Rittenberg CN, Robertson CL, Bizette GA, Gorman B, Marques CB. Preserving dose-intensity in an active regimen in NSCLC with navelbine + mitomycin + cisplatin. Proc Am Soc Clin Oncol 1996; 15: A1123.
15. [15] Gridelli C, Rossi A, Palazzolo G, Pepe R, Airoma G, Incoronato P, Bianco AR. Mitomycin C etoposide and vinorelbine (MEV II) in the treatment of metastatic Stage IV non-small cell lung cancer. Tumori 1994; 80: 128-130.
16. [16] Hoffman P, Drinkard L, Masters G, Samuels B, Krauss S, Watson S, Golomb H, Vokes E. Ifosfamide plus navelbine: a Phase I study in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1995; 14: A1092.
17. [17] Hryniuk W, Levine M. Analysis of dose intensity for adjuvant chemotherapy trials in Stage II breast cancer. J Clin Oncol 1986; 4: 1162-1170.
18. [18] Jacoulet P, Breton JL, Westeel V, Mercier M, Garnier G, Depierre A. Phase I study of vinorelbine and carboplatin in advanced non-small cell lung cancer. Lung Cancer 1995; 12: 247-257.
19. [19] Kaplan E, Meier F. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 58: 457-81.
20. [20] Le Chevalier T, Brisgand D, Douillard J, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari, S, Gottfried M, Ruffle P, Panizo A, Gaspard MH, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P, Tursz T. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-367.
21. [21] Lemarie E, Taytard A, Muir JF, Cordier JF, Dabouis G, Jeannin L, Depierre A. Les alternatives au cisplatine: étude de Phase II d'une combinaison Navelbine® étoposide. In: Pierre Fabre Oncologie, editor. Navelbine®, actualités et perspectives. Paris-Londres: John Libbey Eurotext Ltd, 1990; 159-163.
22. [22] Mangeney P, Andriamialisoa RZ, Lallemand JY, Langlois N, Langlois Y, Potier P, 5′-Noranhy-drovinblastine. Prototype of a new class of vinblastine derivatives. Tetrahedron 1979; 35: 2175-2179.
23. [23] Marangolo M, Intini C. Vinorelbine (VB) + cisplatin (DDP) + etoposide (E) in the treatment of non-operable non-small cell lung cancer (NSCLC). Eur J Cancer 1993; 29A (suppl 6): A905.
24. [24] Marantz A, Lewi D, Litovska S. Phase II study of vinorelbine and ifosfamide for non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1994; A1071.
25. [25] Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981, 47: 207-214.
26. [26] Monnier A, Riviere A, Douillard JY, Milleron B. Lemarie E, Trillet-Lenoir V, Sun XC, Ibrahim N, Appere C, Soulas F, Hua A. Phase II study of docetaxel (taxotere®) and vinorelbine in chemotherapy naive patients with advanced non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 1996; 15: A1129.
27. [27] Morere JM, Israel L, Brunet A, Boaziz, Breau JL. Ifosfamide (IFX) and navelbine (NVB) for unresectable non-small cell lung cancer (NSCLC). Lung Cancer 1994; 11 (suppl 1): A439.
28. [28] Pawel JV, Schroeder M, Grote-Kiehn J, Kerpel-Fronius S, Tresca P, Westerhausen M. Ifosfamide (IFO) + vinorelbine (VRL) as treatment for advanced, non operable non-small cell lung cancer (NSCLC). Lung Cancer 1994; 11 (suppl 1): A444.
29. [29] Recchia F, De Filippis S, Lococo A, Vaccarili M, Terenzi S, Campisi C, Lalli A. Phase II study of navelbine (NVB), ifosfamide (ifo) and carboplatin (CBDCA), in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Oncol 1996; 15: A1101.
30. [30] Richardet E, Lazaris C, Uribe A, Carranza L, Cresta C, Tolocka H, Casarin O. Phase II study: vinorelbine (N) + etoposide (E) + cisplatin (C) in non operable non-small cell lung cancer (NSCLC). Eur J Cancer 1993; 29A (suppl 6): A888.
31. [31] Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Ganz PA, Kaasa S, Pater JL, Quoix E, Rapp E, Tumarello D, Williams J, Woods BL, Bernard JP. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19-21.
32. [32] Toussaint C, Izzo J, Spielmann M, Merle S, May-Levin F, Armand JP, Lacombe D, Tursz T, Sunderland M, Chabot GG, Cvitkovic E. Phase I/II trial of continuous infusion of vinorelbine for advanced breast cancer. J Clin Oncol 1994; 12: 2102-2112.
33. [33] Tredaniel J, Dieras V, Ferme C, Marty M, Hirsch A. Alternative to cisplatin: 5-FU-Navel-bine® combination. In: Pierre Fabre Oncologie, editor. Navelbine®, actualités et perspectives. Paris-Londres: John Libbey Eurotext Ltd, 1990; 165-171.
34. [34] Viallet J, Laberge F, Martins H, Maksimiuk A, Rapp E, Bélanger K. Marceau A, Prady C, St-Louis J, Laplante J, Delorme F. Docetaxel alternating with cisplatin and vinorelbine: early evidence of additive activity in a Phase II trial of non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1996; 15: A1115.
35. [35] Yokes EE, Drinkard LC, Samuels BL, Hoffman PC, Watson S, Bitran JD, Haraf DJ, Ferguson MF, Golomb HM. A Phase II study of cisplatin, 5-fluorouracil and leucovorin augmented by vinorelbine (navelbine) for advanced non-small cell lung cancer: rationale and study design. Semin Oncol 1994; 21 (suppl 10): 79-84.
36. [36] WHO Handbook for reporting results of cancer treatment. WHO offset publication 1979; No 48. Geneva, Switzerland, World Health Organization.